ClinicalTrials.gg
Active, not recruitingNCT05559359ADorable-1Updated Jul 30, 2026

A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

A Phase 3 interventional study of Lebrikizumab and Placebo in Atopic Dermatitis and Eczema, sponsored by Eli Lilly and Company. Active, not recruiting at 85 sites in 12 countries. Open to participants aged 6 Months to 17 Years. Per ClinicalTrials.gov, last updated 2026-07-30.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
377
Allocation
Randomized
Ages
6 Months to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing lebrikizumab in Dermatitis, Atopic — 4 open to participants now, 7 under way, 4 of them phase 3. lebrikizumab · Dermatitis, Atopic.

Enrollment
5th of 24
377 · median 252
Started
2022
with 1 other
Phase 3
17 of 24
2 open now
Registered
14th of 24
by date
Lead sponsor
14 of 24
Eli Lilly and Company

Among the 24 studies testing lebrikizumab in Dermatitis, Atopic, this one is the 5th largest by enrollment, is one of 2 that started in 2022, is one of 17 in phase 3, and was the 14th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

4 of the 24 studies testing lebrikizumab in Dermatitis, Atopic are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About lebrikizumab

lebrikizumab: first FDA approval 2024 (EBGLYSS), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 6 Months to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing lebrikizumab in Dermatitis, Atopic, or all of them as a file.
02

Study summary

The main purpose of this study is to measure the effect, safety and how well the body absorbs lebrikizumab in pediatric participants 6 months to \<18 years of age with moderate-to-severe atopic dermatitis (AD).

03

Conditions studied

  • Atopic Dermatitis
  • Eczema
04

Who can participate

Ages eligible
6 Months to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a diagnosis of AD prior to screening as stated in the criteria by the American Academy of Dermatology for at least,

    • 12 months if participants are ≥6 years of age
    • 6 months if participants are 2 to \<6 years of age
    • 3 months if participants are 6 months to \<2 years of age.
  • Have an EASI score ≥16 at the screening and baseline
  • Have an IGA score ≥3 (scale of 0 to 4) at the screening and baseline
  • Have ≥10% BSA of AD involvement at the screening and baseline.

Exclusion criteria

Exclusion Criteria:

  • Are currently enrolled or have participated within the last 8 weeks in a clinical study involving an intervention or any other type of medical research judged not to be scientifically or medically compatible with this study.
  • Treatment with the following prior to the baseline:
  • An investigational drug within 8 weeks or less than 5 half-lives, whichever is longer.
  • Dupilumab within 8 weeks. Note: The enrollment of participants with prior use of Dupilumab will be limited to \<20%.
  • Treatment with a topical investigational drug within 2 weeks prior to the baseline.
  • Have received a Bacillus Calmette-Guerin vaccination or treatment within less than 4 weeks before randomization.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
377 participants (actual)

Study arms

  • Experimental
    Lebrikizumab (Cohort 1)

    Participants who are 6 years to \<18 years of age, 12 years to \<18 years of age who weigh \<40 kilogram (kg) or 6 years to \<12 years of age (may weigh ≥40 kg) will receive a loading dose and then subsequent doses by subcutaneous (SC) injections with a topical corticosteroid (TCS). Dosing will be based on weight.

    Drug: Lebrikizumab · Drug: Topical Corticosteroid (TCS)

  • Experimental
    Lebrikizumab (Cohort 2)

    Participants who are 6 months to \<6 years of age, 2 years to \<6 years of age or 6 months to \<2 years of age will receive a loading dose of lebrikizumab and then subsequent doses by SC injections with a TCS. Dosing will be based on weight.

    Drug: Lebrikizumab · Drug: Topical Corticosteroid (TCS)

  • Placebo comparator
    Placebo

    Participants will receive placebo matching lebrikizumab by SC injections with a TCS.

    Drug: Placebo · Drug: Topical Corticosteroid (TCS)

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants with an Investigator Global Assessment (IGA) score 0 or 1 and a Reduction ≥2 points from Baseline

    EASI-75 is a co-primary endpoint with IGA.

    Time frame: Baseline to Week 16

  2. Percentage of Participants Achieving Eczema Area and Severity Index-75 (EASI-75) ≥75% Reduction from Baseline in EASI Score

    IGA is a co-primary endpoint with EASI-75.

    Time frame: Baseline to Week 16

Secondary outcomes

  1. Percentage of Participants Achieving EASI-90, a ≥90% Reduction from Baseline in EASI Score

    Time frame: Baseline to Week 16

  2. Percentage of Participants with a Pruritus Numeric Rating Score (NRS) of ≥4 points at Baseline Who Achieve a ≥4-point Reduction from Baseline

    Time frame: Baseline to Week 16

  3. Percentage of Participants with a cDLQI of ≥6 points at Baseline Achieving ≥6-point Improvement in cDLQI from Baseline to Week 16

    Time frame: Baseline to Week 16

  4. Percentage Change from Baseline in EASI Score

    Time frame: Baseline, Week 16

  5. Percentage Change from Baseline in Pruritus NRS Score

    Time frame: Baseline, Week 16

  6. Change from Baseline in Children Dermatology Life Quality Index (cDLQI)

    Time frame: Baseline, Week 16

  7. Mean Change from Baseline in Worst Scratch/Itch Numeric Rating Score (WSI-NRS)

    Time frame: Baseline, Week 16

  8. Change from Baseline in Body Surface Area (BSA)

    Time frame: Baseline, Week 16

  9. Percentage Change from Baseline in Scoring Atopic Dermatitis (SCORAD)

    Time frame: Baseline, Week 16

  10. Percentage of Participants Achieving EASI-50, a ≥50% Reduction from Baseline in EASI Score

    Time frame: Baseline to Week 16

  11. Pharmacokinetics (PK): Average Serum Lebrikizumab Concentration

    Time frame: Week 14

  12. Percentage of Participants with Positive Responses by the Modified Subcutaneous Administration Assessment Questionnaire (mSQAAQ)

    Time frame: Week 14

  13. Percentage of Participants with a Worst Scratching/Itching NRS of ≥4 points at Baseline Who Achieve a ≥4-point Reduction from Baseline to Week 16

    Time frame: Baseline to Week 16

  14. Change from Baseline in SCORAD

    Time frame: Baseline, Week 16

07

Study locations

85 sites
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in Jan 2026, 38 months.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 38 months is above that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2022
First posted
Sep 29, 2022
StartActual
Oct 18, 2022
Primary completionActual
Jan 14, 2026
CompletionEst.
Dec 2026
Last update
Jul 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05559359
Collaborators
Dermira, Inc.
Responsible party
Sponsor
First posted
Sep 29, 2022
Start date
Oct 18, 2022
Primary completion
Jan 14, 2026
Completion
Dec 2026 (estimated)
Last update
Jul 30, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lebrikizumab

Start the discussion